Siemens Healthineers Expands Production Site in Rudolstadt, Germany and Creates New Jobs

Siemens HealthineersSiemens Healthineers is expanding its site in Rudolstadt, Germany. By mid 2024, a new manufacturing building will be built on the site. The new manufacturing plant will produce electron accelerators that will be used as radiation sources for Varian's cancer therapy devices. Varian has been a Siemens Healthineers company since 2021. The hall will also expand the production line for so-called liquid metal plain bearings, a core technology of high-end computed tomography and angiography systems. The expansion of the site is expected to create around 50 new jobs by 2027. Siemens Healthineers is investing around €25 million in the 2100-square-meter manufacturing facility. The new building is to be built in a CO2-neutral manner and operated as sustainably as possible. "The expansion in Rudolstadt is a strong commitment to the location and the entire region. We want to grow here, create jobs and remain an attractive employer," says Peter Schardt, Chief Technology Officer of Siemens Healthineers and responsible for Rudolstadt as a technology location.

In order to meet the growing demand for Varian's radiotherapy equipment, the company needs a second manufacturing site for core components of its radiotherapy devices in addition to Palo Alto in the USA. In Rudolstadt, Siemens Healthineers has the necessary knowledge and already manufactures such components. The electron accelerators from Rudolstadt are to be used for the Halcyon and TrueBeam radiotherapy systems, some of which are manufactured at the Kemnath site in Germany.

Radiotherapy with so-called linear accelerators is one of the most important methods of modern cancer therapy and is used in more than half of all cancer treatments today. Linear accelerators are used both in the outpatient sector and in hospitals for the targeted treatment of cancer.

Today, around 270 employees develop and produce vacuum components, X-ray tubes and components for medical and industrial use at the Rudolstadt plant. The components are used, for example, in computed tomography, angiography systems or mammography devices. The site is also the manufacturing center for industrial electron linear accelerator systems, which are used, among others, in non-destructive material testing and scanning to check contents of shipping containers, trucks and train cars. The plant in Rudolstadt was founded in 1919.

About Siemens Healthineers

Siemens Healthineers AG (listed in Frankfurt, Germany: SHL) pioneers breakthroughs in healthcare. For everyone. Everywhere. As a leading medical technology company headquartered in Erlangen, Germany, Siemens Healthineers and its regional companies are continuously developing their product and service portfolio, with AI-supported applications and digital offerings that play an increasingly important role in the next generation of medical technology. These new applications will enhance the company’s foundation in in-vitro diagnostics, image-guided therapy, in-vivo diagnostics, and innovative cancer care. Siemens Healthineers also provides a range of services and solutions to enhance healthcare providers’ ability to provide high-quality, efficient care. In fiscal 2022, which ended on September 30, 2022, Siemens Healthineers, which has approximately 69,500 employees worldwide, generated revenue of around €21.7 billion and adjusted EBIT of almost €3.7 billion.

Most Popular Now

Giving Doctors an AI-Powered Head Start …

Detection of melanoma and a range of other skin diseases will be faster and more accurate with a new artificial intelligence (AI) powered tool that analyses multiple imaging types simultaneously...

Philips Foundation 2024 Annual Report: E…

Marking its tenth anniversary, Philips Foundation released its 2024 Annual Report, highlighting a year in which the Philips Foundation helped provide access to quality healthcare for 46.5 million people around...

Scientists Argue for More FDA Oversight …

An agile, transparent, and ethics-driven oversight system is needed for the U.S. Food and Drug Administration (FDA) to balance innovation with patient safety when it comes to artificial intelligence-driven medical...

AI Agents for Oncology

Clinical decision-making in oncology is challenging and requires the analysis of various data types - from medical imaging and genetic information to patient records and treatment guidelines. To effectively support...

Start-ups in the Spotlight at MEDICA 202…

17 - 20 November 2025, Düsseldorf, Germany. MEDICA, the leading international trade fair and platform for healthcare innovations, will once again confirm its position as the world's number one hotspot for...

AI Medical Receptionist Modernizing Doct…

A virtual medical receptionist named "Cassie," developed through research at Texas A&M University, is transforming the way patients interact with health care providers. Cassie is a digital-human assistant created by Humanate...

Using Data and AI to Create Better Healt…

Academic medical centers could transform patient care by adopting principles from learning health systems principles, according to researchers from Weill Cornell Medicine and the University of California, San Diego. In...

AI Tool Set to Transform Characterisatio…

A multinational team of researchers, co-led by the Garvan Institute of Medical Research, has developed and tested a new AI tool to better characterise the diversity of individual cells within...

AI Detects Hidden Heart Disease Using Ex…

Mass General Brigham researchers have developed a new AI tool in collaboration with the United States Department of Veterans Affairs (VA) to probe through previously collected CT scans and identify...

Highland Marketing Announced as Official…

Highland Marketing has been named, for the second year running, the official communications partner for HETT Show 2025, the UK's leading digital health conference and exhibition. Taking place 7-8 October...

Human-AI Collectives Make the Most Accur…

Diagnostic errors are among the most serious problems in everyday medical practice. AI systems - especially large language models (LLMs) like ChatGPT-4, Gemini, or Claude 3 - offer new ways...

MHP-Net: A Revolutionary AI Model for Ac…

Liver cancer is the sixth most common cancer globally and a leading cause of cancer-related deaths. Accurate segmentation of liver tumors is a crucial step for the management of the...